Recent News

• 03.11.2025 - Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
• 03.11.2025 - Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
• 03.07.2025 - Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
• 03.07.2025 - Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
• 03.04.2025 - Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
• 03.04.2025 - Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
• 02.10.2025 - Capricor Therapeutics to Participate in Upcoming Investor Conferences
• 02.10.2025 - Capricor Therapeutics to Participate in Upcoming Investor Conferences

Recent Filings

• 03.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 8-K Current report
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - EX-99.1 EX-99.1
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.05.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 01.30.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors